Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Expenses: 2020-2025

Historic Operating Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $235.4 million.

  • Apellis Pharmaceuticals' Operating Expenses fell 3.57% to $235.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $936.0 million, marking a year-over-year decrease of 0.27%. This contributed to the annual value of $946.3 million for FY2024, which is 3.57% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Operating Expenses of $235.4 million as of Q3 2025, which was up 11.15% from $211.8 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Operating Expenses ranged from a high of $250.1 million in Q1 2025 and a low of $124.6 million during Q1 2021.
  • Its 3-year average for Operating Expenses is $232.5 million, with a median of $234.4 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first spiked by 97.30% in 2021, then fell by 15.37% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Operating Expenses (Quarterly) stood at $149.7 million in 2021, then grew by 24.73% to $186.7 million in 2022, then grew by 23.66% to $230.9 million in 2023, then climbed by 3.38% to $238.7 million in 2024, then decreased by 3.57% to $235.4 million in 2025.
  • Its last three reported values are $235.4 million in Q3 2025, $211.8 million for Q2 2025, and $250.1 million during Q1 2025.